mutant BRAF Inhibitors
2 drugsAbout mutant BRAF
Mutant BRAF is a mutated form of the BRAF protein, a serine/threonine kinase involved in cell signaling pathways that control cell growth and proliferation. Mutations in the *BRAF* gene can lead to uncontrolled activation of these pathways, driving tumor development.
Mutant BRAF has emerged as a significant oncology target, though no genetic evidence directly links specific *BRAF* mutations to particular diseases in this dataset. The clinical success of drugs targeting mutant BRAF underscores its importance as a therapeutic target.
Two FDA-approved drugs target mutant BRAF: SORAFENIB TOSYLATE (Viatris) and NEXAVAR (Bayer), both small molecules. These drugs have applications in oncology and other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Fibrolamellar Carcinoma with only 2 trials.
- phase2 represents biological uncertainty with 57% completion.
Top mutant BRAF Drugs
The competitive landscape includes Viatris and Bayer, the only companies with approved drugs.
Low market concentration suggests opportunities for new entrants, but high barriers to entry.
mutant BRAF Drug Modality Landscape
Modalities
Routes of Administration
mutant BRAF is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore opportunities for novel modalities like antibodies or PROTACs to differentiate from existing therapies.
mutant BRAF Clinical Trials 379 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 155 | 113 | 33 | 8 | 77% |
| Phase 2 | 166 | 98 | 46 | 21 | 68% |
| Phase 3 | 53 | 34 | 11 | 8 | 76% |
| Phase 4 | 5 | 4 | 1 | 0 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
mutant BRAF Drug Approval Timeline (2005 - 2020)
The first drug was approved in 2005, with the most recent approval in 2020, spanning 16 years.
The approval timeline indicates a mature target, suggesting potential market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 113 clinical trials targeting mutant BRAF.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities